Mentice AB (“Mentice” or the “Company”) has been listed on Nasdaq First North Premier and completed a new share issue in connection with the listing.
The trading in Mentice’s shares on Nasdaq First North Premier commenced on 18 June 2019. The Company is traded under the ticker symbol MNTC. The offering in connection with the listing was substantially oversubscribed, was targeted at the general public in Sweden and institutional investors in Sweden and abroad and comprised a new issue of SEK 82 million as well as a sale of existing shares of SEK 392 million. The price in the offering was set to SEK 49 per share, which corresponds to a market value of approximately SEK 1.2 billion for the total number of shares in the Company after the offering.
Mentice is a company that offers high-technology solutions for simulation to the medical sector with focus on the fast-growing market for endovascular procedures. Mentice’s simulators are used to educate, train, and improve the practitioners’ skills in different types of interventions and when introducing new clinical instruments. The Company offers “flight simulations” for physicians and clinical teams to provide practitioners with experiences as realistic as possible. Mentice’s purpose is to reduce deaths, injuries, and costs resulting from medical errors and inefficiencies by developing innovative and inspirational tools for the improvement of clinical skills. Headquartered in Gothenburg, Sweden, Mentice has a strong global presence with companies established in the US, Japan, China, and Switzerland.